Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCamden Capital, LLC
Latest Disclosed Ownership5,929 shares
Latest Disclosed Value $ 2,647,510
Camden Capital, LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 11, 2026 - Camden Capital, LLC filed a 13F-HR form disclosing ownership of 5,929 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,647,536 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 6,439 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -7.92% during the quarter. The current value of the position is $2,649,255 USD.

Camden Capital, LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 5,929 -510 -7.92 2,648 -9.32 0.1736
2026-01-30 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,439 941 17.12 2,919 35.58 0.1837
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,498 2,189 66.15 2,153 46.16 0.1478
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,309 139 4.38 1,473 -4.10 0.1386
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,170 -132 -4.00 1,537 15.58 0.1613
2025-01-29 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,302 -480 -12.69 1,330 -24.45 0.1444
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,782 -737 -16.31 1,759 -16.95 0.1899
2024-08-06 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,519 431 10.54 2,118 24.00 0.1688
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,088 1,508 58.45 1,709 62.82 0.1499
2024-02-05 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,580 433 20.17 1,050 40.62 0.1062
2023-11-03 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,147 339 18.75 747 17.30 0.0879
2023-08-09 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,808 821 83.18 636 105.16 0.0723
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 987 141 16.67 311 27.05 0.0459
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 846 -2,697 -76.12 244 -76.22 0.0387
2022-11-08 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,543 2,754 349.05 1,026 362.16 0.2382
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 789 789 222 0.0579
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,225 -100.00 0 -100.00
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,225 106 9.47 269 31.86 0.0465
2021-11-03 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,119 -36 -3.12 204 -12.45 0.0407
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,155 -23 -1.95 233 -7.91 0.0538
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,178 188 18.99 253 8.12 0.0679
2021-02-04 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 990 990 234 0.0753
2020-08-11 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,446 -100.00 0 -100.00
2020-04-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,446 -31 -2.10 338 4.64 0.1874
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,477 1,477 323 0.1545
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-04-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS COM Put 1,000 219 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.